PFE · 8-K · 20261103PR000132

CFO Leadership Transition

PFIZER INC · 2026-11-03 · Importance 25 · Surprise 42

Pfizer appointed Cecile Guegan Chief Financial Officer and Executive Vice President, effective November 1, 2026. Guegan had served as interim CFO since August 16, 2026, and had more than 25 years of pharmaceutical finance experience. She will oversee corporate finance functions including audit, treasury, investor relations, tax, insurance, planning and analysis, controllership, and business finance and analytics. Before becoming interim CFO, she was responsible for financial operations and reporting for Pfizer’s biopharmaceutical business across therapeutic areas and geographies.

Key facts

• Pfizer’s Board of Directors unanimously appointed Cecile Guegan Chief Financial Officer and Executive Vice President, effective November 1, 2026. source
• Cecile Guegan said her focus as CFO is to execute disciplined capital allocation and make targeted investments to drive revenue growth later in the decade and beyond. source
• As Chief Financial Officer, Cecile Guegan will oversee every aspect of Pfizer’s financial management and all corporate finance functions, including audit, treasury, investor relations, tax, insurance, operations planning and analysis, corporate controllership, and business finance and analytics. source
• Cecile Guegan had served as Pfizer’s interim Chief Financial Officer since August 16, 2026. source
• Cecile Guegan has more than 25 years of pharmaceutical finance experience. source
• Before becoming interim finance leader, Cecile Guegan was responsible for the financial operations and reporting of Pfizer’s biopharmaceutical business across all therapeutic areas and geographies. source
• Cecile Guegan previously led long-term forecasting for key product portfolios, led major enterprise acquisitions and integrations, and co-led a strategic initiative to identify new sources of growth. source